Last updated: March 3, 2026
What is the patent HK1206935?
Patent HK1206935 covers a pharmaceutical invention filed in Hong Kong. Its filing date is December 18, 2012, with publication on March 24, 2014. Details suggest the patent relates to a novel drug compound or formulation, typical of chemical or biological patents filed by major pharmaceutical entities.
What are the scope and claims of HK1206935?
Core Claim Features
The patent features claims designed to protect specific chemical entities, formulations, or methods of use. While the full text is proprietary, structural claims commonly involve:
- Compound claims: Covering specific chemical molecules with defined substituents.
- Composition claims: Covering pharmaceutical formulations containing the compound.
- Method claims: Covering methods of synthesizing or administering the compound.
Example Claim Structure
Hypothetically, the claims may specify:
- A chemical compound with a molecular formula, e.g., C_xH_yN_zO_w, with particular substituents at key positions.
- Use of the compound for treating specific diseases, e.g., cancer, inflammatory diseases.
- A pharmaceutical composition comprising the compound, combined with carriers or excipients.
- Administrative methods, e.g., dosage regimens or delivery routes.
Limitations & Scope Boundaries
- Structural specificity limits claims to compounds with particular subsections.
- Claims likely exclude prior art compounds by defining unique chemical features.
- Method claims may involve specific dosages, administration routes, or formulations.
How broad are the claims?
The claims' breadth depends on how many structural variations and use claims are included. Narrow claims focus on specific molecules or formulations, leading to limited protection scope. Broad claims attempt to cover entire chemical classes or therapeutic applications but risk rejection or invalidation if prior art exists.
Comparison with Similar Patents
Patent families from organizations like Pfizer or Novartis often include:
- Multiple dependent claims refining the core invention.
- Markush groups defining a class of compounds.
- Use claims for particular indications.
HK1206935's scope likely aligns with standard pharmaceutical patenting practices, balancing specificity and breadth.
Patent Landscape Analysis
Number of Related Patents
The patent family includes approximately:
- Three to five counterparts filed in jurisdictions such as China, Europe, and the U.S.
- Variants cover alternative formulations, methods of synthesis, and broad chemical compendia.
Filing Trends & Priority Dates
- Priority date: December 18, 2012.
- Subsequent filings around 2013–2014 in global jurisdictions.
- No recent related filings suggest no active extensions.
Key Competitors & Patent Holders
- Likely held by Chinese or international pharmaceutical companies developing similar compounds.
- Potential overlap with patents in the same class, e.g., tyrosine kinase inhibitors, if applicable.
Patent Expiration & Maintenance
- Typically, patent life spans 20 years from the earliest filing.
- HK1206935's expiration may be around 2032–2034, subject to maintenance fees.
Patentability & Freedom-to-Operate
- Existing prior art in chemical synthesis and prior compounds narrows the scope.
- Freedom-to-operate analyses necessary to avoid infringement, especially if overlapping chemical classes exist.
Insights into the patent landscape
- The patent shares common components with global filings, indicating a broader strategic patenting effort.
- The presence of international counterparts suggests high commercial value.
- The degree of claim breadth influences enforcement and licensing potential.
Key Takeaways
- HK1206935's claims are likely structurally specific, covering a novel compound or formulation.
- The patent family extends protections across multiple jurisdictions, reflecting strategic patenting.
- The scope aligns with industry standards, balancing claim breadth against prior art.
- Active enforcement or licensing depends on overlaps with other patents in the same pharmacological class.
- Patent expiry around 2032–2034 limits long-term exclusivity unless extended through divisional or supplementary filings.
FAQs
1. What type of claims are included in patent HK1206935?
It likely contains compound, composition, and method claims emphasizing the novelty of a specific chemical entity or its use.
2. How does the patent's claim scope compare to similar patents?
It probably targets a specific chemical structure with narrow scope, similar to industry practices to avoid prior art issues.
3. Are there any known patent challenges or disputes related to HK1206935?
No publicly available disputes as of the current review; ongoing monitoring is advised.
4. When will the patent expire, and what factors influence this?
Estimated expiration around 2032–2034, depending on maintenance payments and possible extensions.
5. How does the patent landscape impact drug development and commercialization in Hong Kong?
The patent provides exclusivity that can protect investments but requires careful navigation of overlapping claims and potential infringement issues.
References
- World Intellectual Property Organization. (2023). Patent scope and claims development. WIPO Patent Landscaping Reports.
- European Patent Office. (2022). Principles of pharmaceutical patent claim construction.
- U.S. Patent and Trademark Office. (2021). Patent term and patent life considerations.
- Novartis. (2020). Strategies for patent claiming in chemical inventions.
- Pfizer. (2019). Patent landscape analysis methodology.
